Background It is widely accepted that intellectual property legal requirements such as
patents and data exclusivity can affect access to medicines, but to date there has not been a …

Objective To compare the market dynamics of biosimilar infliximab among four Organization
for Economic Cooperation and Development (OECD) countries (UK, France, Japan, and …

Background Monoclonal antibody (mAb) and Fc-fusion protein (FcP) are highly effective
therapeutic biologics. We aimed to analyse consumption and expenditure trends in 14 Asia …

Biosimilars have had a sizeable impact on the availability and use of biologic medicines in
Australia, particularly those prescribed for supportive care in oncology or to treat …

Die Arzneimitteltherapie bei Frauen im gebärfähigen Alter ist jedoch schlecht dokumentiert.
Das geht aus unseren Umfrageergebnissen hervor. Nur wenige Frauen, die bereits vor ihrer …

Objective To examine whether non‐medical switching of patients with inflammatory bowel
disease (IBD) from originator infliximab to a biosimilar (CT‐P13, Inflectra) is safe and …

Biosimilars are increasingly adopted to improve affordability of biologics. An effective
introduction of biosimilars requires an understanding of patient acceptance of these agents …

Commentary other issues. 21 After more than seven years of negotiations, pressure is
mounting on countries to sign the agreement within the next 12 months, with India …

Background Biosimilar medicines are defined as biological products highly similar to an
already licensed biological product (RP). The market entry of biosimilars is expected to …

Despite their availability for over a decade, the exact nature of biosimilar medicines is still
poorly understood with paucity of clear treatment guidelines for their use in clinical practice …